Evidence map›Paper›PMID 42689245›Full record

ArticleJBMR plus2026

Impact of FRAXplus adjustments vs FRAX on fracture risk classification in the Swiss Osteoporosis Registry.

Carla Martignoni, Oliver Lehmann, Mathias Wenger, Sven Oser, Martin Toniolo, Gernot Schmid, Ueli Studer, Hans-Rudolf Ziswiler, Christian Steiner, Anna Thoma and 11 more

Abstract read
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Carla MartignoniDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Oliver LehmannDepartment of Information Technology and Electrical Engineering, ETH Zürich, Zürich, Switzerland.ORCID https://orcid.org/0009-0009-2690-5055
Mathias WengerZentrum für Rheuma- und Knochenerkrankungen, Hirslanden Klinik Im Park, Zürich, Switzerland.
Sven OserZentrum für Rheuma- und Knochenerkrankungen, Hirslanden Klinik Im Park, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-3487-6444
Martin TonioloZentrum für Rheuma- und Knochenerkrankungen, Hirslanden Klinik Im Park, Zürich, Switzerland.
Gernot SchmidDepartment of Rheumatology, Lucerne Regional Hospital, Lucerne, Switzerland.
Ueli StuderOsteoRheuma Bern, Bern, Switzerland.
Hans-Rudolf ZiswilerOsteoRheuma Bern, Bern, Switzerland.
Christian SteinerOsteoRheuma Bern, Bern, Switzerland.
Anna ThomaDepartment of Rheumatology and Pain Medicine, Bethesda Hospital, Basel, Switzerland.ORCID https://orcid.org/0009-0003-2162-0751
Ferdinand KrappelDepartment of Orthopedics, European Spine Centre of Excellence, Brig, Switzerland.ORCID https://orcid.org/0000-0001-6165-2289
Piero PancaldiRheumatology Outpatient Center, Muralto (Ticino), Switzerland.
Maki KashiwagiGynosense, Women's Health Center, Uster, Switzerland.
Diana FreyGynosense, Women's Health Center, Uster, Switzerland.
HansJörg HäuselmannZentrum für Rheuma- und Knochenerkrankungen, Hirslanden Klinik Im Park, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-6174-0980
Britta MaurerDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland.ORCID https://orcid.org/0000-0001-9385-8097
Stephan ReichenbachDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland.ORCID https://orcid.org/0000-0001-8098-6567
Helena JohanssonMellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
Thomas LehmannOsteoRheuma Bern, Bern, Switzerland.
Eugene McCloskeyMellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.ORCID https://orcid.org/0000-0003-0177-8140
Judith Everts-GraberDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland.ORCID https://orcid.org/0000-0002-8792-8199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FRAXplus complements the fracture risk assessment tool (FRAX) by incorporating additional risk factors to adjust 10-yr probabilities of major osteoporotic and hip fractures. We aimed to identify which adjustments most strongly influence fracture risk estimates and how they affect risk classification and treatment recommendations in Switzerland. We analyzed data from the Swiss Osteoporosis Registry (2015-2023), which captures all standard FRAX variables plus lumbar spine (LS) BMD, trabecular bone score (TBS), fall history in the previous year, oral glucocorticoid dosages, and the location and recency of prior fractures. Data on hip axis length and duration of type 2 diabetes were not available. A total of 28 708 individuals (88% women; mean age 65.8 ± 11.4 yr) were included, with a median 10-yr probabilities for major osteoporotic fracture (MOF) of 16% (interquartile range [IQR]: 9-24) using standard FRAX and 18% [IQR: 11-28] with FRAXplus adjustments. Most individuals (72%) had higher probabilities with FRAXplus (mean absolute increase: +4.8%), while 27% had lower probabilities (mean absolute decrease: -1.0%). TBS and LS minus FN T-score (LS - FN) influenced nearly all risk estimates, but differences between FRAX and FRAXplus were generally modest. At the individual level, ≥1 fall and recent vertebral or hip fractures produced the largest differences. Applying FRAXplus with Swiss intervention thresholds led to an upward reclassification in 16% of MOF estimates and a downward reclassification in 1%. In summary, FRAXplus adjustments significantly alter fracture risk estimates for most individuals. While LS BMD and TBS affect most probabilities, falls and recent vertebral or hip fractures have the largest absolute impact at the individual level, leading to clinically relevant changes in treatment recommendations according to Swiss guidelines.

Indexed as

BMDfracture predictionFRAXFRAXplusosteoporosisrisk factors

Identifiers

PMID42689245
PMCPMC13537462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.